Sarepta jumps 19% as fears ebb over superiority of Pfizer DMD data

Sarepta Therapeutics (SRPT +19.4%) is up more than double normal as investors buy in after Pfizer’s (PFE) data presentation this morning on DMD gene therapy candidate PF-06939926. Apparently, interim data from a small Phase 1 study was on par with Sarepta’s AAVrh74.

PFE is up a fraction on below-average volume.

https://seekingalpha.com/news/3474644-sarepta-jumps-19-percent-fears-ebb-superiority-pfizer-dmd-data